Zhengxiang X. Han
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Blood Lead Levels and Mortality Risk in Cancer Patients: A Prospective Cohort Study with Mediation and Pan-Cancer Pathway Analysis.
Journal: Biological trace element research
Published: June 07, 2026
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.
Journal: Future oncology (London, England)
Published: June 03, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Journal: Lancet (London, England)
Published: April 23, 2026
Single- and dual-target CAR-T cells targeting HBsAg and GPC3 to balance safety and antitumor efficacy in HBV-positive hepatocellular carcinoma.
Journal: iScience
Published: January 30, 2026
Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress gene FKBP10 in gastric cancer.
Journal: Translational cancer research
Published: December 17, 2025
Association between diarrhea and survival in patients with HER2-positive advanced breast cancer treated with pyrotinib-based therapy: A landmark analysis from the real-world PRETTY study.
Journal: Breast (Edinburgh, Scotland)
Published: November 28, 2025
Effect of the Evidence-Based and Multidisciplinary Pain Management Program in Patients After Laparoscopic Hepatectomy: A Quasi-Experimental Study.
Journal: Journal of pain research
Published: November 16, 2025
Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics.
Journal: Clinical epigenetics
Published: September 09, 2025
Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058).
Journal: Frontiers in pharmacology
Published: August 15, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Journal: Lancet (London, England)
Published: July 23, 2025
Clinical significance of androgen receptor in unilateral invasive breast cancer in women.
Journal: European journal of medical research
Published: April 04, 2025
Last Updated: 09/26/2026